利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.01 秒)

    POLYMORPHIC FORM OF PRIDOPIDINE HYDROCHLORIDE
    1.
    发明公开
    POLYMORPHIC FORM OF PRIDOPIDINE HYDROCHLORIDE 有权
    多聚甲醛形式

    公开(公告)号：EP2753603A1

    公开(公告)日：2014-07-16

    申请号：EP12755869.0

    申请日：2012-09-06

    申请人： IVAX INTERNATIONAL GMBH

    发明人： SONESSON, Clas ,  PITTELKOW, Thomas ,  FRØSTRUP, Brian ,  ZIMMERMANN, Anne

    IPC分类号： C07D211/24 ,  A61K31/445 ,  A61P25/28

    CPC分类号： C07D211/30 ,  C07D211/24

    摘要： This invention relates to a new crystalline form of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides polymorphic Form II of the Pridopidine hydrochloride salt, a process for the preparation this polymorphic form, pharmaceutical compositions comprising polymorphic Form II, and methods of uses of this polymorphic form.

    摘要翻译： 本发明涉及一种新的结晶形式的派多定，目前正在开发用于治疗亨廷顿氏病的药物。 更具体地，本发明提供了盐酸普拉头可苷的多晶型II，制备该多晶形式的方法，包含多晶型II的药物组合物，以及该多晶型形式的使用方法。

    PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
    4.
    发明公开
    PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY 审中-公开
    药物组合物联合治疗

    公开(公告)号：EP2844346A1

    公开(公告)日：2015-03-11

    申请号：EP13772325.0

    申请日：2013-04-03

    申请人： IVAX International GmbH

    发明人： WATERS, Ross, Nicholas ,  WATERS, Eva, Susanna

    IPC分类号： A61P25/14

    摘要： This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.

    N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES
    7.
    发明授权
    N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES 有权
    多巴胺受体稳定剂/ WITH IMPROVED环流心脏的副作用分布调节剂的N-氧化物和/或二 - N-氧化物衍生物

    公开(公告)号：EP2146961B1

    公开(公告)日：2014-01-29

    申请号：EP08741904.0

    申请日：2008-04-11

    申请人： IVAX International GmbH

    发明人： WIKSTRÖM, Håkan, V.

    IPC分类号： C07D211/94 ,  A61K31/451 ,  A61P25/06 ,  A61P25/14 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

    CPC分类号： C07D211/94

    摘要： A compound having the general formula wherein A is selected from the group consisting of to the formation of a compound of the general formula (1) and a compound of the general formula (2) respectively, and pharmaceutically acceptable salts thereof, wherein R1 is a member selected from the group consisting of CF3, OSO2CF3, OSO2CH3, SOR4, SO2R4, COR4, CN, OR4, NO2, CONHR4, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br and I, wherein R4 is as defined below; R2 is a member selected from the group consisting of H, F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, NH2, SOmCF3, O(CH2)mCF3, SO2N(R4)2, CH═NOR4, COCOOR4, COCOON(R4)2, (C1-C8)alkyl, (C3-C8)cykloalkyl, CH2OR4, CH2(R4)2, NR4SO2CF3, NO2, at phenyl at positions 2, 4, 5 or 6, wherein x and R4 are as defined below; R3 is a member selected from the group consisting of hydrogen, CF3, CH2CF3, (C1-C8)alkyl, (C3-C8)cykloalkyl, (C4-C9)cycloalkylmethyl, (C2-C8)alkenyl, (C2-C8)alkynyl, 3,3,3-tri-fluoropropyl, 4,4,4-trifluorobutyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, phenylethyl, 2-thiopheneethyl and 3-thiopheneethyl; R4 is a member selected from the group consisting of hydrogen, CF3, CH2CF3, (C1-C8)alkyl, (C3-C8)cycloalkyl, (C4-C9)cycloalkylmethyl, (C2-C8)alkenyl, (C2-C8)alkynyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2-tetrahydrofurane and 3-tetrahydrofurane; X is selected from the group consisting of N and sp3-hybridized C; Y is selected from the group consisting of O and, when R3 represents H, OH; Z is selected from the group consisting of H and OH when X is sp3-hybridized C or Z represents O or an electronic lone-pair when X is N; the dashed line represents a bond when X is sp2-hybridized C or is absent when X is N; m is an integer 1 or 2; n is an integer 1-3; provided that when n in Formula 1 is 2, R1 is SO2CH3 and R2 is H R3 does not represent n-propyl. The invention also relates to a pharmaceutical preparation containing said compound, the use of said compound for the manufacture of a pharmaceutical composition and a method for the treatment of a disorder in the central nervous system of a patient using said compound.